Found 216 of kd data for polymerid = 3373,3688,50007185 TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0150nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0150nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0310nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0310nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0510nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0510nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0650nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0650nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0820nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0820nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0860nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0860nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0880nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.0880nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.140nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.140nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.200nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.200nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.204nMAssay Description:Binding affinity to wild type human biotinylated and N-terminal DYKDDDDK-tagged TrkA kinase domain (436 to 790 residues) expressed in Sf21 cells asse...More data for this Ligand-Target Pair
3D Structure (crystal)TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.230nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.230nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.700nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) by SPR assayMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.810nMAssay Description:Binding affinity to human partial length TRKA expressed in mammalian expression system by kinomescan methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.880nMAssay Description:Binding affinity to human partial length TRKA expressed in mammalian expression system by kinomescan methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 0.940nMAssay Description:Binding affinity to His-tagged TrkA (unknown origin) after 1 hr by SPR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 1nMAssay Description:Binding affinity to DNA-tagged human partial length TrkA expressed in mammalian expression system by qPCR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 1nMAssay Description:Binding affinity to human partial length TRKA expressed in mammalian expression system by kinomescan methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 1.10nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) assessed as dissociation rate...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 1.60nMAssay Description:Binding affinity to wild-type human partial length TRKA (G475 to G790 residues) expressed in mammalian expression system by Kinomescan method relativ...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 1.60nMAssay Description:Binding affinity to DNA-tagged human partial length TrkA expressed in mammalian expression system by qPCR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2nMAssay Description:Average Binding Constant for NTRK1; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.10nMAssay Description:Binding affinity to human partial length TRKA expressed in mammalian expression system by kinomescan methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.30nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) by SPR assayMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.30nMAssay Description:Binding affinity to DNA-tagged recombinant human TRKA (475 to 790 residues) expressed in mammalian expression system by KINOMEscan assayMore data for this Ligand-Target Pair
Ligand Info
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.5nMAssay Description:Binding affinity to DNA-tagged human partial length TrkA expressed in mammalian expression system by qPCR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.60nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) by SPR assayMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 2.90nMAssay Description:Binding affinity to human partial length TRKA expressed in mammalian expression system by kinomescan methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 3.20nMAssay Description:Binding affinity to DNA-tagged human partial length TrkA expressed in mammalian expression system by qPCR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 3.5nMAssay Description:Binding affinity to His-tagged TrkA (unknown origin) after 1 hr by SPR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4nMAssay Description:Binding constant for TRKA kinase domainMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4nMAssay Description:Binding affinity to DNA-tagged human partial length TrkA expressed in mammalian expression system by qPCR methodMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4nMAssay Description:Binding constant for TRKA kinase domainMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4.20nMAssay Description:Binding affinity to C-terminal-His6/N-terminal BAP-tagged unphosphorylated TrkA (unknown origin) (441 to 796 residues) by SPR analysisMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4.5nMAssay Description:Binding constant for TRKA kinase domainMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4.70nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) assessed as dissociation rate...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 4.80nMAssay Description:Binding constant for TRKA kinase domainMore data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 5.70nMAssay Description:Binding affinity to un phosphorylated C-terminal His6/N-terminal BAP-tagged TrkA (441 to 796 residues) (unknown origin) assessed as dissociation rate...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 6nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
TargetHigh affinity nerve growth factor receptor(Homo sapiens (Human))
Turning Point Therapeutics, Inc.
US Patent
Turning Point Therapeutics, Inc.
US Patent
Affinity DataKd: 6nMAssay Description:Kinase binding assays were performed at DiscoveRx using the general KINOMEscan Kd Protocol (Fabian, M. A. et al., “A small molecule-kinase interactio...More data for this Ligand-Target Pair
